Serum Institute of India, Pune-based vaccine manufacturer has launched two more vaccines for rotavirus causing diarrhea and rabies and is working away at a few more from dengue to cervical cancer.
The recently developed Rabishield anti-rabies vaccine is claimed to be the world’s first recombinant rabies monoclonal antibody acting agent to prevent forestall Rabies, a fatal disease which is estimated to cause two deaths consistently in India.
In a research partnership with Massachusetts Medical School USA, Rabishield has been developed. Adar Poonawalla, Chief Executive Officer, Serum Institute of India, while propelling the antibodies in Mumbai said, “Rabishield is a first-of-its-kind product for passive immunization against rabies. Since the new medication will be 25 percent less expensive than the current rabies immunoglobulins, it would meet the needs of the poor nations”.
‘Rotasiil’ rotavirus vaccine is claimed to be the world’s first thermostable pentavalent Rotavirus vaccine containing the G9 strain to help prevent the spread of rotavirus which causes diarrhea for the most part in babies and is frequently accompanied by vomiting and fever, leading to severe dehydration. It is reported that around 100,000 rotavirus-related deaths occur in India.
Serum’s researchers have been working on this rotavirus vaccine throughout the previous eight years and the heat-stable vaccine was developed to conquer the absence of cold-chain in many poor nations, said Poonawalla.
Adar Poonawalla said, Serum Institute is also planning to launch a biologic medication for dengue in two years, in association with a US organization company. The company is additionally developing a dengue vaccine, which might be developed in three to four years. The serum is additionally working on to launch 3-4 new vaccines, including for cervical growth, pneumococcal and meningitis.
The privately held Rs 4,000 crore revenue company wants to reach over Rs 10,000 crore in the following five years with the new launches and sales in developed markets.
Begun in 1966 by Dr. Cyrus Poonawalla, Serum Institute of India sells around 1.3 billion doses of different a year all around across over 147 nations.
Around 65 percent children on the world are estimated to have received no less than one vaccine made by Serum, whose products are available in more than 147 nations.